Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Q1 2026 and Recent Financial Performance
RVTY logo

Revvity Reports 7% Revenue Growth to $711 Million and Announces Strategic China Divestiture

RVTY8-KFiling Date: 5/5/2026
Revvity, Inc.
Description

What this story covers

Revvity, Inc. reported strong Q1 2026 results with 711 million dollars in revenue and 6 percent pro forma organic growth. The company is optimizing its portfolio through the planned divestiture of its China Immunodiagnostics business while maintaining robust cash flow.

Story snapshot

CompanyRevvity, Inc.
TickerRVTY
VariantStandard detailed
Duration5:39
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000031791-26-000016
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in